Lung Cancer

ICI Use in Patients with NSCLC After Radiotherapy Associated with Severe Pneumonitis
Web Exclusives | September 26, 2022
Patients with non–small-cell lung cancer with a history of prior radiotherapy before immune checkpoint inhibitor treatment are at increased risk for developing severe pneumonitis.
Identifying Best Practices and Gaps in Late-Stage Lung Cancer: From Diagnosis and Staging Through Survivorship and/or End of Life
Nancy Collar, RRT-NPS, AE-C, ACCS, Brooke O’Neill, MSN, RN, Kim Parham, BSN, RN, CN-BN, Shawn Perkins, BSN, RN, OCN, Amy Jo Pixley, MSN, RN, OCN, ONN-CG(T), Emily Gentry, BSN, RN, HON-ONN-CG, OCN
September 2022 Vol 13, No 9 | September 19, 2022
In the United States, the second most commonly diagnosed cancer in both men and women is lung cancer, including both non–small-cell lung cancer (NSCLC) and small-cell lung cancer (SCLC).
Importance of Early Detection in Lung Cancer: Elevating the Navigator’s Role
July 2022 Vol 13, No 7 | July 25, 2022
Is your navigation program offering these vital services to the people that need them the most?
2022 Midyear Review: Non–Small-Cell Lung Cancer
Special Issues and Supplements | July 21, 2022
Anxiety and Depression in Advanced Lung Cancer Patients Affected by Symptoms and Therapy
Web Exclusives | June 28, 2022
Anxiety and depression in patients with advanced lung cancer are associated with poor outcomes when untreated. Radiotherapy, breathlessness, and fatigue are among top predictors of these debilitating conditions.
Pretreatment Prognostic Score May Determine Immunotherapy Response in Advanced NSCLC
Web Exclusives | June 28, 2022
Study evaluates factors that may help determine whether a patient with advanced non–small-cell lung cancer may benefit from the use of immune checkpoint inhibitors.
KRAS G12C Mutation Associated with Female Sex and Risk of Central Nervous System Metastasis
Web Exclusives | June 28, 2022
In patients with non–small-cell lung cancer, KRAS G12C mutation is associated with female sex, smoking, and adenocarcinoma and the risk of development of central nervous system metastasis.
Development of Immune-Related Adverse Events in Patients with Advanced NSCLC
Web Exclusives | June 28, 2022
Analysis reveals factors associated with the development of immune-related adverse events in patients with advanced non–small-cell lung cancer treated with immunotherapy.
Despite High Biomarker Testing Rates Result Turnaround Time Remains Treatment Decision Barrier
Web Exclusives | May 24, 2022
Recent survey results of physicians who treat patients with non–small-cell lung cancer reveal high biomarker testing rates, but treatment decisions frequently depend on test result turnaround time.
Longer Overall Survival Found in Patients with Lung Cancer Adhering to Tumor Board Recommendations
Web Exclusives | May 24, 2022
Newly diagnosed patients who adhered to tumor board recommendations for treatment have a longer overall survival time than patients who only partially adhered or did not adhere to recommendations.
Loading More Articles
Page 5 of 23
Results 41 - 50 of 230

Subscribe Today!

To sign up for our print publication or e-newsletter, please enter your contact information below.

I'd like to receive:

  • First Name *
    Last Name *
     
     
    Profession or Role
    Primary Specialty or Disease State
    Country
SUBSCRIBE

Contact Us | Editorial Board

© 2009- DBA AONN+ Academy of Oncology Nurse & Patient Navigators® PO Box 563, Cranbury, NJ 08512